文献速递胸部肿瘤放疗姑息放疗与转移瘤

纳武利尤单抗联合立体定向体部放疗治疗晚期非小细胞肺癌的随机2期试验

A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-12-19

NIVORAD研究将化疗后进展的转移性非小细胞肺癌患者随机分配至纳武利尤单抗单药组或联合单次SABR组,主要终点6个月无进展生存率两组相似(49% vs 44%),客观缓解率和总生存也无显著差异,且未增加不良事件。

要点

  • 联合SABR未增加3-5级不良事件,安全性可控。

核心结论

  • 在化疗后进展的转移性NSCLC中,纳武利尤单抗联合SABR与单药疗效和安全性相似,未增加不良事件。

研究设计与样本

  • 患者按1:2随机分配至纳武利尤单抗单药组(n=16)或联合单次SABR组(n=34)。
  • 纳入免疫治疗初治、经1-2线化疗后进展、有适合SABR病灶的转移性NSCLC成人患者。
  • 纳武利尤单抗240 mg每2周一次直至疾病进展或不可耐受毒性,SABR单次18-20 Gy。
  • 主要终点为6个月无进展生存率,次要终点包括客观缓解率、总生存、1年和2年PFS及不良事件。

主要发现

  • 客观缓解率联合组24%(8/34) vs 单药组25%(4/16)。
  • 3-5级严重不良事件发生率联合组77%(24/31) vs 单药组75%(12/16)。
  • 每组各1例死亡(肺炎和呼吸衰竭)。

关键数值与推荐

  • 客观缓解率:联合组24%(8/34) vs 单药组25%(4/16)。
  • 3-5级不良事件:联合组77%(24/31) vs 单药组75%(12/16)。

临床怎么用

  • 对于化疗后进展的转移性NSCLC,纳武利尤单抗联合单次SABR未显示优于单药,不推荐常规联合。
  • 联合方案未增加严重不良事件,但需注意免疫相关肺炎等风险。

局限性

  • 对照组女性比例较高(56% vs 35%),可能存在基线不平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Programmed cell death protein-1 inhibitors have improved metastatic non-small cell lung cancer (NSCLC) prognosis. Stereotactic ablative body radiation therapy (SABR) may enhance immunity. This study evaluated the activity and safety of adding SABR to first-line immunotherapy post chemotherapy with nivolumab for metastatic NSCLC. METHODS AND MATERIALS: NIVORAD (ALTG14/002/CT0135/TROG 16.01) randomized adults (1:2) to nivolumab 240 mg 2-weekly until disease progression or prohibitive toxicity either alone, or with single fraction SABR (18-20 Gy). Eligible patients had metastatic NSCLC, had progressed after 1-2 lines of chemotherapy, were immunotherapy-naïve, and had a disease site suitable for SABR. The primary endpoint was progression free survival (PFS) at 6 months. Secondary endpoints were objective tumor response rate, overall survival, PFS at 1 and 2 years, and adverse events (AEs). The planned sample size of 120 was to provide 80% power with a 1-sided type 1 error rate of 5% to distinguish the observed proportions alive and progression free at 6 months. The study closed early because of slow accrual. RESULTS: Fifty participants were recruited and randomly assigned to nivolumab alone (n = 16) or nivolumab plus SABR (n = 34). Baseline characteristics were balanced across treatment arms, apart from percentage of females which was higher in the control arm (56% vs 35%). Median follow-up was 26 months. PFS was similar among those assigned nivolumab plus SABR versus nivolumab alone (PFS at 6 months 49% vs 44%, hazard ratio [HR], 0.68; 95% CI, 0.36-1.27; P = .23). Objective tumor response rate (8/34[24%] vs 4/16[25%]) and overall survival (HR, 0.86; 95% CI, 0.43-1.75; P = .69) were also similar in the 2 treatment groups. Rates of serious grade 3-5 AE (12/16 (75%) vs 24/31 (77%) in experimental arm) were also similar in the 2 groups. There were 2 deaths, 1 in each treatment group (pneumonitis and respiratory failure). CONCLUSIONS: Nivolumab plus SABR demonstrated similar efficacy and safety to nivolumab alone in metastatic NSCLC progressing after chemotherapy, without increased AEs.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kothari G, O'Byrne KJ, Brown C, et al. A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). Int J Radiat Oncol Biol Phys. 2025. PMID: 41422917. doi:10.1016/j.ijrobp.2025.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。